echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The second domestic one!

    The second domestic one!

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 3, China’s National Food and Drug Administration announced that WuXi Biotech's CAR-T product targeting CD19, Recchio-cel (trade name: Benoda), has been officially approved


    Source: State Drug Administration

    Ruijio Lun Sai injection (formerly known as: Rui Ji Lun Sai injection) is an anti-CD19 CAR-T product developed by WuXi Juno, which is intended to treat various B cell malignant tumors.


    Public information shows that the CAR expressed by the T cells of Ruiji Orenxel injection combined with the extracellular domain of CD19 can cause the intracellular domain of CAR to promote T cell expansion and trigger effector functions to eliminate tumor cells


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.